LATEST NEWS
 Top Stories
 U.S.
  Severe Weather
  Bird Flu
 World
  Castro
  Mideast Crisis
  Iraq
 Business
 Personal Finance
 Technology
 Sports
  Sports Columns
  NASCAR
  Baseball
  College Hoops
  NBA
  NHL
  Tennis
  Golf
 Entertainment
 Health
 Science
 Politics
 Washington
 Offbeat
 Podcasts
 Blogs
 Weather
 Raw News
 NEWS SEARCH
 
 Archive Search
 SPECIAL SECTIONS
 Multimedia Gallery
 AP Video Network
 Today
 in History
 Corrections
Nov 8, 6:35 PM EST

FDA OKs drug to block infection after marrow transplant


AP Photo
AP Photo/Matt Rourke

Multimedia
When Drugs Stop Working
Lone Protestor Rallies Ohio City Against Drugs
From Drug Addict to Counselor
Documents
CDC Report on Sexual Behavior and Drug Use
Latest News
Correction: FDA-Transplant Drug story

FDA OKs drug to block infection after marrow transplant

Multimedia
Drug war interactive

TRENTON, N.J. (AP) -- U.S. regulators have approved the first drug to prevent life-threatening infections in adults after a bone marrow transplant.

The Food and Drug Administration on Wednesday approved sales of Merck and Co.'s Prevymix (PREH'-vih-miss) to prevent infections with cytomegalovirus (sy-toe-MEG'-a-low-vy-rus), a common virus. It doesn't sicken most people, but strikes at least half of transplant patients, who are particularly vulnerable to infection. The virus can damage the eyes, lungs and other organs, trigger pneumonia and even kill.

Kenilworth, New Jersey-based Merck says the drug will cost $195 to $270 per day for 100 days.

Each year, about 8,500 Americans receive transplants of blood-forming cells from bone marrow to treat blood cancers or other blood disorders. Currently, they get antiviral therapy if they develop an infection, rather than a preventive treatment.

---

This story has been corrected to show that the number of Americans receiving bone marrow transplants is about 8,500 each year, not 20,000.

© 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Learn more about our Privacy Policy and Terms of Use.